A potential second Trump administration would likely continue prioritizing deregulation and market-driven healthcare solutions. During his first term, former President Trump emphasized reducing government involvement in healthcare, favoring policies that foster competition among providers and insurers. That first term “was characterized by efforts to chip away at key tenets of the Affordable Care Act, curtail the Medicaid program, and deregulate the healthcare industry.” [Healthcare Dive November 7, 2024] Key areas of focus may include the Affordable Care Act (ACA), drug pricing, and healthcare transparency.
The Trump administration’s repeated efforts to dismantle the ACA suggest that a second term could reignite efforts to repeal or replace key components, such as the Medicaid expansion or marketplace subsidies. These changes could have significant implications for hospitals and providers, particularly those serving low-income or underserved populations. Any substantial alterations to Medicaid would ripple through the healthcare sector, affecting revenue streams and patient coverage.
Drug pricing reform, a hallmark of Trump’s first term, may resurface with policies aimed at lowering prescription costs. Initiatives like drug importation or international price indexing could challenge pharmaceutical companies but offer savings to consumers and insurers. These proposals, however, often face legal and industry pushback, delaying their implementation. Some indication about the impact on the pharmaceutical industry was exposed by the stock market where pharmaceutical stocks gained value after the election results were known. This doesn’t speak well for the consumer/patient.
Transparency initiatives would likely remain a priority. Trump’s executive orders requiring hospitals and insurers to disclose negotiated rates sought to empower consumers and reduce costs. A second administration could expand such mandates, further pushing the industry toward price transparency. Transparency efforts for both hospitals and insurers seem ineffectual.
Healthcare providers may also encounter more flexibility through continued deregulation. Measures like expanded telehealth reimbursement and reduced reporting requirements, initiated during the COVID-19 pandemic, align with the administration’s market-oriented approach and could become permanent features.
While the Trump administration’s policies often favored cost reduction and deregulation, the industry remains cautious about potential disruptions, especially concerning insurance coverage and funding for safety-net providers. The healthcare sector should prepare for a blend of continuity and renewed regulatory challenges under a second Trump presidency.
